Acrivon Therapeutics, Inc.

Stage 2 · Advancing · week 7

As of Oct 22, 2026, Acrivon Therapeutics is in Stage 2, the uptrend phase, now in week 7 (since Sep 4, 2026). It closed at $1.76, 41.5% below its 52-week high and below its 200-day average, which is falling.

$1.76

-6.68% today

$75.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ACRV early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 29w

S4 34w

S1 18w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 2w → S4 29w → S1 6w → S2 8w → S3 8w → S2 6w → S3 8w → S4 34w → S1 18w → S2 8w → S3 7w → S4 6w → S1 11w → S4 4w → S1 2w → S2 7w current

Total tracked: 165 weeks across 16 stage runs.

ACRV among Biotechnology228th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…228	ACRVAcrivon Therapeutics, Inc.	Stage 2 · wk 7	44	−14.6%

vs 52W High

-41.5%

$1.29 lo$3.01 hi

41.5% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 7

1w13w26w

Week 7, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-0.9%

200 DMA: $1.78 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.28x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-14.6%

+10.0%

-6.9%

YTD

-28.5%

-13.7%

Scan Membership

Breakout Watch

Latest: 2024-08-26

2 appearances in last 60 days. First seen: 2024-05-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 7 · Vol 0.28x

2026-10-21S2

Wk 7 · Vol 0.49x

2026-10-20S2

Wk 7 · Vol 0.57x

2026-10-19S2

Wk 7 · Vol 0.37x

2026-10-16S2

Wk 6 · Vol 0.80x

2026-10-15S2

Wk 6 · Vol 0.35x

2026-10-14S2

Wk 6 · Vol 0.65x

2026-10-13S2

Wk 6 · Vol 1.46x

2026-10-12S2

Wk 6 · Vol 0.42x

2026-10-09S2

Wk 5 · Vol 0.57x

2026-10-08S2

Wk 5 · Vol 1.22x

2026-10-07S2

Wk 5 · Vol 0.83x

Moving averages & range

50 DMA

$1.98

200 DMA

$1.78

52W High

$3.01

52W Low

$1.29

5D Low

$1.64

Resistance levels (recent highs)

20d High

$2.10

60d High

$2.39

120d High

$2.39

250d High

$3.01

Next resistance

+19.3%

to 20d High

ROE

-64.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.9

Acrivon Therapeutics: quick answers

What stage is Acrivon Therapeutics in?

As of Oct 22, 2026, Acrivon Therapeutics (ACRV) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 4, 2026 and is in week 7. What the four stages mean

Is Acrivon Therapeutics in an uptrend?

Yes. Acrivon Therapeutics is in a Stage 2 uptrend. It trades 0.9% below its 200-day average, which is falling.

How far is Acrivon Therapeutics from its 52-week high?

Acrivon Therapeutics closed at $1.76 on Oct 22, 2026, 41.5% below its 52-week high of $3.01. Its 52-week low is $1.29.

How has Acrivon Therapeutics performed over the past year?

As of Oct 22, 2026, Acrivon Therapeutics is down 13.7% over the past year and down 28.5% so far in 2026.

Which sector and industry is Acrivon Therapeutics in?

Acrivon Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.